Monograph Details
|
|
Central Nervous System
> Mood disorders
|
|
ZYPREXA INTRAMUSCULAR |
| Manufacturer |
|
Lilly, Eli and Company |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Thienobenzodiazepine. |
| Generic Name |
|
Olanzapine 10mg/vial; IM inj after reconstitution. |
| Also |
• ZYPREXA
• ZYPREXA ZYDIS
|
| Indications |
|
Agitation due to bipolar I mania. |
| Children |
|
Not recommended. |
| Adults |
|
Give by deep IM inj. Usual range: 2.5mg–10mg/dose. Elderly: 5mg. Debilitated, risk of hypotension, or sensitive to olanzapine: 2.5mg. All: up to 3 doses daily (2–4 hrs apart); switch to oral form when appropriate. Severe orthostatic hypotension: not recommended. |
| Precautions |
|
Diabetes risk factors (obtain baseline fasting blood sugar). Monitor for hyperglycemia. Cardio- or cerebrovascular disease. Hypovolemia. Dehydration. Seizures. Hepatic impairment (monitor ALT/AST). GI or GU obstruction. Narrow angle glaucoma. History of paralytic ileus or breast cancer. Exposure to extreme heat. Reevaluate periodically. Dysphagia. Suicidal ideation. Write Rx for smallest practical amount. Elderly (esp. with dementia). Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Orthostatic hypotension with antihypertensives, alcohol, benzodiazepines, others. Avoid alcohol. Caution with other CNS drugs, drugs that lower seizure threshold, anticholinergics, and with hepatotoxic agents. May antagonize levodopa, dopamine agonists. May be antagonized by rifampin, omeprazole, carbamazepine, others that induce CYP1A2 or glucuronyl transferase. May be potentiated by fluvoxamine, others that inhibit CYP1A2. Smokers may have increased metabolism. |
| Adverse Reactions |
|
Somnolence, dry mouth, dizziness, asthenia, constipation, weight gain, dyspepsia, abnormal gait, increased appetite, tremor, fever, back or chest pain, postural hypotension, tachycardia, hypertension, peripheral edema, hyperglycemia, tardive dyskinesia, worsening of parkinsonian symptoms, neuroleptic malignant syndrome, hyperprolactinemia, increased ALT; others. |
| How Supplied |
Tabs—30, 60, 1000
Zydis—30
Vial—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
